Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Marvel Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,791,036

832 payments

Through program year 2025, Marvel Clinical Research LLC is reported as receiving $2,791,036 in research payments, across 832 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $300,577 50
2024 Research $587,374 221
2023 Research $362,080 185
2022 Research $646,091 229
2021 Research $162,181 33
2020 Research $183,095 37
2019 Research $549,636 77

Breakdown

Who paid Research payments · program years 2019–2025
  1. Incyte Corporation $1,202,558 517 payments
  2. AbbVie, Inc. $526,608 62 payments
  3. Organon LLC $520,688 113 payments
  4. GlaxoSmithKline, LLC. $187,917 11 payments
  5. Seqirus USA Inc $161,724 105 payments
  6. AstraZeneca Pharmaceuticals LP $99,460 4 payments
  7. VYNE Pharmaceuticals Inc. $68,914 14 payments
  8. Pfizer Inc. $14,495 3 payments
  9. Endo Pharmaceuticals Inc. $6,100 1 payment
  10. Myovant Sciences Inc. $1,600 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema $580,418 252 payments
  2. M16-100 $494,594 46 payments
  3. Og-8175A-023 $352,140 57 payments
  4. A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo $187,896 31 payments
  5. A Phase I/II Observer-Blind, Randomized, Multi-Center Trial to Evaluat $169,320 4 payments
  6. Og-8175A-023 $168,548 56 payments
  7. A Phase 2b, Randomized, Observer-Blind, Antigen and Adjuvant Dose-Confirmation Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine (aQIVc) in Older Adults =50 Years of Age $161,724 105 payments
  8. A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo $123,281 57 payments
  9. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $99,460 4 payments
  10. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa $82,446 19 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $520,688 113 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record